Grants8 | The most comprehensive grants search on the web

Grant Analysis

Purpose & Target

This grant aims to drive innovation in surgical interventions for cancer treatment, specifically for patients with locally advanced or metastatic disease. It seeks to validate new, affordable, and multi-modal therapeutic approaches through clinical trials. - Target recipient type: Broad range of organizations including research institutions, SMEs, public health bodies, and NGOs. - Target size: Not explicitly limited, but projects are large-scale requiring significant capacity. - SECTOR-SPECIFIC (Oncology, Healthcare, Medical Devices, Research & Innovation) - Geographic scope: EU Member States and Associated Countries. - Key filtering criteria: Focus on innovative surgical treatments for advanced/metastatic cancer, clinical trial validation, and consortium-based applications. - Grant frequency: Recurring as part of the Horizon Europe Mission on Cancer annual work programme.

Financial Structure

Total budget for this topic (HORIZON-MISS-2025-02-CANCER-03) in 2025: 31000000.0 EUR.
Minimum grant amount per project: 7000000.0 EUR.
Maximum grant amount per project: 10000000.0 EUR.
Expected number of grants: 4.
Currency: EUR.
Funding rate: None specified for this particular call. Horizon Europe RIA grants typically fund up to 100% of eligible costs for non-profit entities and up to 70% for for-profit entities (e.g., SMEs).
Eligible costs: Include costs for networking, attendance at meetings, and joint activities, as proposals 'should include a budget for networking, attendance at meetings, and joint activities'.
Co-financing requirements: Not explicitly stated, but depends on the legal status of the recipient (profit vs. non-profit).
Financial reporting and audit requirements are described in 'Annex G of the Work Programme General Annexes'.

Eligibility Requirements

Organizational Type and Structure

Eligible organization types include a broad mix of stakeholders:
Research and innovation organizations (e.g., universities, research centres)
Small and Medium-sized Enterprises (SMEs)
Public healthcare providers and authorities (e.g., regional/national health authorities)
Non-governmental organizations (NGOs), charities, foundations, civil society organizations
Professional bodies (e.g., physicians, engineers, physicists, patient representatives, insurance companies)
Consortium or partnership is required. Proposals must 'include an appropriate mix of stakeholders from various disciplines and sectors'.

Geographic Requirements

Open to legal entities established in EU Member States and Associated Countries. This includes:
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
Albania, Bosnia and Herzegovina, Georgia, Iceland, Israel, Moldova, Montenegro, North Macedonia, Norway, Serbia, Turkey, Ukraine, United Kingdom (Note: Associated countries list can vary; check official Horizon Europe Programme Guide for the definitive current list).

Technical and Capacity Requirements

Capacity to conduct 'academic investigator-initiated clinical trials' is essential.
Expertise in 'innovative surgery-centred, multi-modal treatment interventions', medical devices, oncology, and relevant clinical research methodologies.
Requirement for effective contribution of Social Sciences and Humanities (SSH) disciplines, involving SSH experts and institutions.
Ability to handle and disaggregate data by sex, gender, age, socio-economic status, and other relevant variables.
Adherence to 'open science' principles and data sharing via the 'EU dataset catalogue of the European Health Data Space' and 'future UNCAN.eu platform'.
Capability to build on resources from the 'Knowledge Centre on Cancer (KCC)'.

Exclusion Criteria

Specific exclusion criteria are described in 'Annex C of the Work Programme General Annexes' (not detailed here, but typically relate to financial viability and legal standing).

Application Process

Application Timeline and Deadlines

Submission opening date: 2025-05-06.
Application deadline: 2025-09-16 00:00:00+00.
Submission procedure: 'single-stage'.
Indicative timeline for evaluation and grant agreement is described in 'Annex F of the Work Programme General Annexes'.

Required Documentation and Submission Materials

Application must use the 'Standard application form (HE RIA, IA)' available in the Submission System.
A specific application form for this call is available in the Submission System.
Applicants must provide details of the clinical studies in a 'dedicated annex using the template provided in the submission system'.
Proposal page limits and layout are described in 'Part B of the Application Form' and 'Annex A and Annex E of the Horizon Europe Work Programme General Annexes'.

Application Procedure and Platform

Applications must be submitted electronically through the 'Funding & Tenders Portal'.
Access to the submission service requires authentication (EU Login or third-party sign-in).
Applicants will confirm their choice of action type and model grant agreement in the submission system.

Application Assistance and Support

'Online Manual': Comprehensive guide from proposal submission to grant management.
'Horizon Europe Programme Guide': Detailed guidance on structure, budget, and political priorities.
'Funding & Tenders Portal FAQ': Answers to common questions.
'Research Enquiry Service': For general questions about European research.
'National Contact Points (NCPs)': Guidance and assistance on participation in Horizon Europe (also available in non-EU/non-associated countries).
'Enterprise Europe Network (EEN)': Advice for businesses, especially SMEs, including EU research funding guidance.
'IT Helpdesk': For technical issues related to the Funding & Tenders Portal.
'European IPR Helpdesk': Assistance on intellectual property issues.
'CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk': Advice on standardisation in proposals.
'Partner Search': Tool to find partner organizations for proposals.

Evaluation Criteria

Evaluation criteria are based on 'Annex D of the Work Programme General Annexes', with specific thresholds for this call. Excellence

Score threshold: 4
Scientific and technological quality of the project proposal (including methodology).
Novelty and innovative aspects of the proposed surgery-centred, multi-modal treatment interventions.
Soundness of the proposed 'academic investigator-initiated clinical trials' for validating interventions.
Robustness of the chosen intervention(s) adaptation to target population needs and healthcare specificities.

Impact

Score threshold: 4
Contribution to 'overall survival, patient-reported outcomes and quality of life issues' for cancer patients with locally advanced or metastatic disease.
Potential for 'affordable surgery-centred treatment solutions' to be implemented in healthcare systems, supported by cost-effectiveness analysis.
Enhancement of 'equitable access' to tailored and effective cancer treatments.
Contribution to the overall objectives of the 'Mission on Cancer' and its transversal priorities (innovation, personalized medicine, citizen engagement).
Expected social impact through 'social innovation' and 'end-user engagement using participative research models'.
Strategic alignment with broader EU initiatives like the European Green Deal, Zero Pollution Action Plan, and digitalisation strategies.
Data management and sharing plan, including open science principles and use of EU data infrastructures.

Quality and Efficiency of the Implementation

Score threshold: 4
Quality and effectiveness of the work plan, including the appropriateness of the allocation of tasks and resources.
Capability and expertise of the consortium partners, ensuring an 'appropriate mix of stakeholders from various disciplines and sectors'.
Soundness of the management structures and procedures, including risk management.
Appropriateness of the budget for the proposed activities.
Effective engagement with the 'Knowledge Centre on Cancer (KCC)' and participation in the 'Diagnosis and Treatment' cluster for the Cancer Mission.

Compliance & Special Requirements

Regulatory and Ethical Compliance

Regulatory compliance, permits, and authorizations are described in 'Annex B of the Work Programme General Annexes'.
Ethical standards and requirements inherent to conducting clinical trials are expected.
'The European Charter for Researchers and the Code of Conduct for their recruitment' should be consulted for general principles.

Data and Digital Compliance

All datasets produced should be described with 'metadata records in the EU dataset catalogue of the European Health Data Space'.
All tools and models should take advantage of current 'European research infrastructures'.
Principles of 'open science' must be followed.
Data and tools should be made available through the 'future UNCAN.eu platform'.
Integration of 'AI, machine learning and deep learning approaches' is supported for various cancer-related applications.
Compliance with the industrial and digitalisation strategy.

Collaboration and Networking

Successful proposals are expected to 'build on resources made available by the Knowledge Centre on Cancer (KCC)'.
Successful proposals will be asked to join the 'Diagnosis and Treatment' cluster for the Cancer Mission.
A budget should be included for 'networking, attendance at meetings, and joint activities' within this cluster.

Cross-Cutting Themes and Inclusivity

Data should be disaggregated by 'sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity'.
The chosen interventions should reflect the 'cultural diversity and available resources across Member States and Associated Countries'.
Requires 'effective contribution of Social Sciences and Humanities (SSH) disciplines' and involvement of SSH experts.

Strategic Alignment

Projects must contribute to the overall goal of the 'Mission on Cancer' to improve the lives of over 3 million people by 2030.
Alignment with the 'European Green Deal', including the 'Zero Pollution Action Plan' and 'Farm to Fork strategy', is relevant for prevention aspects.

Intellectual Property

'Legal and financial set-up of the grants' described in 'Annex G of the Work Programme General Annexes' will cover intellectual property policies. (No specific details provided in target grant document).

Grant Details